

WINNING THE WAR AGAINST CANCER



MONDAY JUNE 25, 2018



Welcome and opening remarks

The 10th Anniversary of the WIN Consortium: lessons and perspectives
John Mendelsohn, Chairman WIN Consortium; University of Texas MD Anderson Cancer Center (UT-MDACC), USA

PRESIDENTIAL SESSION 1: THE CHALLENGES OF BUILDING REAL COOPERATION TO IMPLEMENT PRECISION ONCOLOGY PROGRAMS: A LONG AND WINDING ROAD

Chairs: *John Mendelsohn, UT-MDACC, USA, Chairman of WIN Consortium; Jean-Charles Soria, MedImmune, USA*



Keynote Lecture: The TAPUR family of clinical trials: building a global data sharing platform in Precision Oncology
Richard L. Schilsky, American Society of Clinical Oncology (ASCO®), USA



The systems biology approach to Precision Oncology: ready to defeat cancer
Leroy Hood, Institute for Systems Biology (ISB), USA



U.S. National Cancer Institute perspective on Precision Oncology
James H. Doroshow, National Cancer Institute (NCI), USA



Beyond standard of care: the next steps of Precision Oncology - an ESMO perspective
Josep Taberero, Vall d'Hebron Institute of Oncology (VHIO), Spain. President European Society for Medical Oncology (ESMO), Switzerland



A view from the European Union on the international collaborations and the future of the Framework programmes
Cornelius Schmalz, Head of Unit Health Research Strategy, Directorate General for Research and Innovation at the European Commission in Brussels, Belgium

Open Forum and Debate with the audience: The key issues of worldwide cooperation

- Technology and conceptual breakthroughs
- Industry or academic sponsored research
- Funding of clinical trials
- Publication policies

Moderators:

Lisa Hutchinson, Foundation for World Health (FWH), UK, WIN Consortium
Jean-Charles Soria, MedImmune, USA

Panel:

James H. Doroshow, NCI, USA
Leroy Hood, ISB, USA
John Mendelsohn, UT-MDACC, USA
Richard L. Schilsky, ASCO, USA
Cornelius Schmalz, European Commission, Belgium
Josep Taberero, VHIO, Spain, ESMO

SESSION 2: THE NEXT FRONTIER OF THERAPEUTICS IN NEWLY DIAGNOSED PATIENTS: STANDARD OF CARE OR MODERN BIOMARKER DRIVEN PRECISION ONCOLOGY?

Chairs: *Razelle Kurzrock, UCSD, USA; Josep Taberero, VHIO, Spain*



Keynote lecture: Preventive and curative healthcare: the next frontier for Precision Oncology
John Wilden, Foundation for World Health (FWH), UK



A new world of early diagnosis to defeat Non-Small Cell Lung Carcinoma (NSCLC)
 The WIN Consortium BOOSTER trial for identification and validation of new blood biomarkers for NSCLC
Amir Onn, Sheba Medical Center, Israel



Lessons from long-term survey of Stage I NSCLC
Harvey I. Pass, New York University, NYU Langone Health, USA



Keynote Lecture: Patients' expectations and hopes
Ellen V. Sigal, Friends of Cancer Research, USA



Newly diagnosed breast cancer at the frontier of precision oncology
Laura Esserman, University of California San Francisco (UCSF), USA

ORGANIZING COMMITTEE

CHAIRS:

John Mendelsohn (USA)
Razelle Kurzrock (USA)

MEMBERS:

Lisa Hutchinson (UK)
Brian Leyland-Jones (USA)
Amir Onn (Israel)
Richard L. Schilsky (USA)
Chang-Sik Yu (South Korea)
Vladimir Lazar (France)
Catherine Bresson (France)

MONDAY JUNE 25, 2018 - CONTINUED

Open forum and debate with the audience: **Next frontiers of therapeutics**

Moderators:

Razelle Kurzrock, UCSD, USA
Josep Taberero, VHIO, Spain

Panel:

Laura Esserman, UCSF, USA
Amir Onn, Sheba Medical Center, Israel
Harvey I. Pass, NYU Langone Health, USA
Ellen V. Sigal, Friends of Cancer Research, USA

WELCOME RECEPTION, NETWORKING AND POSTER VIEWING running at the same time as

MEET THE PROFESSOR sessions to choose from:

- Meeting 1:** James H. Doroshow, National Cancer Institute (NCI), USA
Josep Taberero, Vall d'Hebron (VHIO), Spain; President (ESMO), Switzerland
- Meeting 2:** Richard L. Schilsky, American Society of Clinical Oncology (ASCO), USA
John Mendelsohn, University of Texas, MD Anderson Cancer Center, USA
- Meeting 3:** Ellen V. Sigal, Friends of Cancer Research, USA
- Meeting 4:** Carl H. June, Perelman School of Medicine, USA
Laura Esserman, University of California San Francisco, USA
- Meeting 5:** Francesco De Lorenzo, European Cancer Patient Coalition (ECPC), Belgium

TUESDAY JUNE 26, 2018

SESSION 3: **DISRUPTIVE CONCEPTS AND CLINICAL TRIALS SHIFTING THE PARADIGM OF PRECISION ONCOLOGY**

Chairs: Carl H. June, Perelman School of Medicine, USA; Richard L. Schilsky, ASCO, USA



Keynote Lecture: The tri-antibody methodology for blocking the cancer cells: perspectives
Yosef Yarden, Weizmann Institute of Science, Israel



The first targeted agents tri-therapy combination trial in first therapeutic line of metastatic NSCLC: the WIN Consortium SPRING_01 trial
Razelle Kurzrock, University of California San Diego (UCSD), USA




The challenges of combining targeted therapies in biomarker driven Precision Oncology – a Pharma perspective
Jean-François Martini, Pfizer Inc., USA



MY-pathway study: when biology meets the challenges of Precision Oncology
Mary Beattie, Genentech, USA

SESSION 4: **NEW CONCEPTS AND THERAPEUTICS AVENUES IN PRECISION ONCOLOGY**

Chairs: Alan Spatz, McGill Segal Cancer Center, Canada; Elizabeth H. Blackburn, Salk Institute, USA



Keynote Lecture: Precision CAR T-cells therapeutics
Carl H. June, Perelman School of Medicine, 2017 David A. Karnofsky Memorial Award ASCO®, USA



Importance of prevention and early interception to win the war on cancer
Elizabeth H. Blackburn, Salk Institute, USA



Immunotherapies turning cold in hot tumors
Jean-Charles Soria, MedImmune, USA



Precision Oncology approaches for immunotherapy
Eric Rubin, Merck Research Laboratories, USA

TUESDAY JUNE 26, 2018 - CONTINUED

Open forum and debate with the audience: **The future of drug development for Precision Oncology**

Moderators:

Elizabeth H. Blackburn, Salk Institute, USA
Alan Spatz, McGill Segal Cancer Centre, Canada

Panel:

Carl H. June, Perelman School of Medicine, USA
Jean-François Martini, Pfizer Inc., USA
Eric Rubin, Merck Research Laboratories, USA
Richard L. Schilsky, ASCO, USA

SESSION 5: **THE REGULATORY CHALLENGES OF A NEW MODEL OF DRUG DEVELOPMENT - THE COMBINATION OF TARGETED THERAPIES**

Chair: to be confirmed



The great hits of Precision Oncology
Bernadette Toner, GenomeWeb, USA



Access of patients to Precision Oncology
Francesco De Lorenzo, European Cancer Patient Coalition (ECPC), Belgium

Roundtable and panel discussion

Moderators:

To be confirmed

Panel:

Francesco De Lorenzo, ECPC, Belgium
Bernadette Toner, GenomeWeb, USA

SESSION 6: **10th YEAR OF THE WIN SYMPOSIUM IN THE ERA OF MODERN ONCOLOGY**

Chairs: Vladimir Lazar; Catherine Bresson, WIN Consortium, France

2 best posters presentations and awards

10th ANNIVERSARY CEREMONY OF THE WIN SYMPOSIUM

WIN AWARDS:

- Outstanding career
- Best speaker at WIN symposia
- Best project manager
- Best principal investigator
- Best scientific contribution
- Innovation in Precision Oncology
- Friends of WIN

10TH ANNIVERSARY EVENT